These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 39182542)

  • 21. A novel GLP-1/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson's disease.
    Yuan Z; Li D; Feng P; Xue G; Ji C; Li G; Hölscher C
    Eur J Pharmacol; 2017 Oct; 812():82-90. PubMed ID: 28666800
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative Analysis of Orthosteric and Allosteric GLP-1R Agonists' Effects on Insulin Secretion from Healthy, Diabetic, and Recovered INS-1E Pancreatic Beta Cells.
    Reed J; Higginbotham V; Bain S; Kanamarlapudi V
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928038
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Two novel dual GLP-1/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson's disease.
    Feng P; Zhang X; Li D; Ji C; Yuan Z; Wang R; Xue G; Li G; Hölscher C
    Neuropharmacology; 2018 May; 133():385-394. PubMed ID: 29462693
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Topical Administration of GLP-1 Receptor Agonists Prevents Retinal Neurodegeneration in Experimental Diabetes.
    Hernández C; Bogdanov P; Corraliza L; García-Ramírez M; Solà-Adell C; Arranz JA; Arroba AI; Valverde AM; Simó R
    Diabetes; 2016 Jan; 65(1):172-87. PubMed ID: 26384381
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action.
    Athauda D; Foltynie T
    Drug Discov Today; 2016 May; 21(5):802-18. PubMed ID: 26851597
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Repurposing GLP-1 Receptor Agonists for Parkinson's Disease: Current Evidence and Future Opportunities.
    Victorino DB; Nejm M; Guimarães-Marques M; Scorza FA; Scorza CA
    Pharmaceut Med; 2021 Jan; 35(1):11-19. PubMed ID: 33409802
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
    Skow MA; Bergmann NC; Knop FK
    Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
    [TBL] [Abstract][Full Text] [Related]  

  • 28. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
    Nauck MA; Quast DR; Wefers J; Meier JJ
    Mol Metab; 2021 Apr; 46():101102. PubMed ID: 33068776
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glucagon-like peptide 1 (GLP-1).
    Müller TD; Finan B; Bloom SR; D'Alessio D; Drucker DJ; Flatt PR; Fritsche A; Gribble F; Grill HJ; Habener JF; Holst JJ; Langhans W; Meier JJ; Nauck MA; Perez-Tilve D; Pocai A; Reimann F; Sandoval DA; Schwartz TW; Seeley RJ; Stemmer K; Tang-Christensen M; Woods SC; DiMarchi RD; Tschöp MH
    Mol Metab; 2019 Dec; 30():72-130. PubMed ID: 31767182
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.
    Fisman EZ; Tenenbaum A
    Cardiovasc Diabetol; 2021 Nov; 20(1):225. PubMed ID: 34819089
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mitral cells and the glucagon-like peptide 1 receptor: The sweet smell of success?
    Bagnoli E; FitzGerald U
    Eur J Neurosci; 2019 Feb; 49(4):422-439. PubMed ID: 30120857
    [TBL] [Abstract][Full Text] [Related]  

  • 32. From diabetes to diverse domains: the multifaceted roles of GLP-1 receptor agonists.
    Dave BP; Chorawala MR; Shah IV; Shah NN; Bhagat SU; Prajapati BG; Thakkar PC
    Mol Biol Rep; 2024 Jul; 51(1):835. PubMed ID: 39042283
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunohistochemical assessment of glucagon-like peptide 1 receptor (GLP-1R) expression in the pancreas of patients with type 2 diabetes.
    Kirk RK; Pyke C; von Herrath MG; Hasselby JP; Pedersen L; Mortensen PG; Knudsen LB; Coppieters K
    Diabetes Obes Metab; 2017 May; 19(5):705-712. PubMed ID: 28094469
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders.
    Salcedo I; Tweedie D; Li Y; Greig NH
    Br J Pharmacol; 2012 Jul; 166(5):1586-99. PubMed ID: 22519295
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
    Nauck M
    Diabetes Obes Metab; 2016 Mar; 18(3):203-16. PubMed ID: 26489970
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activation of Glucagon-Like Peptide-1 Receptor Promotes Neuroprotection in Experimental Autoimmune Encephalomyelitis by Reducing Neuroinflammatory Responses.
    Lee CH; Jeon SJ; Cho KS; Moon E; Sapkota A; Jun HS; Ryu JH; Choi JW
    Mol Neurobiol; 2018 Apr; 55(4):3007-3020. PubMed ID: 28456941
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting GLP-1 receptor trafficking to improve agonist efficacy.
    Jones B; Buenaventura T; Kanda N; Chabosseau P; Owen BM; Scott R; Goldin R; Angkathunyakul N; Corrêa IR; Bosco D; Johnson PR; Piemonti L; Marchetti P; Shapiro AMJ; Cochran BJ; Hanyaloglu AC; Inoue A; Tan T; Rutter GA; Tomas A; Bloom SR
    Nat Commun; 2018 Apr; 9(1):1602. PubMed ID: 29686402
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanism of the neuroprotective effect of GLP-1 in a rat model of Parkinson's with pre-existing diabetes.
    Elbassuoni EA; Ahmed RF
    Neurochem Int; 2019 Dec; 131():104583. PubMed ID: 31654678
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances beta-cell function but does not inhibit gastric emptying in mice.
    Maida A; Lovshin JA; Baggio LL; Drucker DJ
    Endocrinology; 2008 Nov; 149(11):5670-8. PubMed ID: 18669601
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pleiotropic effects of glucagon-like peptide-1 (GLP-1)-based therapies on vascular complications in diabetes.
    Yamagishi S; Matsui T
    Curr Pharm Des; 2011 Dec; 17(38):4379-85. PubMed ID: 22204436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.